

Contents

List of tables, figures and boxes	ix
List of abbreviations	xi
About the editors	xv
About the chapter authors	xvii
About the country profile authors	xix
Foreword	xxv
Executive summary	xxvii
PART 1: Overview, conceptual framework and methods	1
Clinical guidelines: background and overview	2
<i>Evidence-based medicine and clinical guidelines</i>	3
<i>Aims and definitions of clinical guidelines</i>	4
<i>The need to evaluate clinical guidelines</i>	8
AGREE	9
Conceptual framework and methodology for the following sections	11
<i>Conceptual framework</i>	11
<i>Methodology</i>	13
PART 2: Mapping clinical guidelines in Europe	17
Background	17
<i>Countries with "well-established" activities</i>	19
<i>Countries "making progress" in the development of clinical guidelines</i>	20
<i>Countries "recently adopting" some guidelines or where these are "in the planning stage"</i>	22
Regulatory basis	22
Quality control	23
AGREE instrument widely used	23
No quality requirement, AGREE instrument often used	25
Countries following an adapted version of AGREE	25
Countries using other instruments	25
No formal processes to assess the quality of clinical guidelines	26
Development	27
<i>Institutions and organizations responsible for developing clinical guidelines</i>	27
<i>Guidelines produced by a central agency</i>	27
<i>Multiple actors are involved and there is a central component in place</i>	27
<i>Multiple actors produce guidance without central coordination</i>	28

Levels of operation	29
<i>Local guidelines are developed by centralized guidelines</i>	29
<i>Centralized guidelines are developed by regional agencies</i>	29
Implementation	30
<i>Mandatory and legal aspects</i>	30
<i>Implementation aids</i>	30
<i>Financial incentives</i>	31
Evaluation	31
<i>Formal evaluation of clinical guidelines</i>	31
<i>No formal evaluations of clinical guidelines</i>	33
Discussion	34
PART 3: Case studies on clinical guidelines for the prevention and treatment of type 2 diabetes mellitus	37
Introduction	37
<i>United Kingdom (England)</i>	38
<i>Germany</i>	42
<i>France</i>	46
<i>Malta</i>	49
<i>Spain</i>	50
<i>Slovenia</i>	52
Conclusions	54
PART 4: Are guidelines in Europe well developed? Are they well implemented? Do they have any impact? A systematic review of the literature	57
Introduction	57
Objectives	58
Methods	58
<i>Search and screening</i>	58
<i>Data extraction and analysis</i>	61
Results	61
<i>Result of the literature search</i>	61
<i>Methodological quality of clinical guidelines</i>	64
<i>Effects of implementation strategies</i>	68
<i>Effectiveness of implementation strategies</i>	69
<i>Impact of clinical guidelines on process of care and patients' health outcomes</i>	73
Discussion	77
Priorities for research	81
Conclusions	81
PART 5: Conclusions, policy recommendations and areas for further study	83
PART 6: European country profiles on clinical guidelines	87
Questionnaire template sent out to authors	87

Austria	88
Belgium	91
Bulgaria	95
Cyprus	97
Czech Republic	99
Denmark	100
Estonia	101
Finland	103
France	105
Germany	106
Greece	108
Hungary	109
Ireland	111
Italy	113
Latvia	115
Lithuania	117
Luxembourg	119
Malta	120
The Netherlands	122
Norway	123
Poland	125
Portugal	126
Romania	127
Slovakia	129
Slovenia	131
Spain	132
Sweden	135
Switzerland	137
United Kingdom (England)	138
References	143
Annex 1: EU Member States' use of guidelines	167
Annex 2: Case studies on the development of clinical guidelines for type 2 diabetes mellitus – template for data collection	215
Annex 3: Systematic review methods tables	217
Afterword: the Latin American perspective	219